IDT and Purui Benchmark Forge Strategic Partnership to Deliver End-to-End Solutions for CGT Drug Development

On March 17, 2026, IDT (Integrated DNA Technologies, a brand under the Danaher Life Sciences platform), a leading provider of nucleic acid synthesis and gene editing tools, officially signed a strategic cooperation agreement with Precision Scientific, a well-known translational medicine platform in China that covers the entire process of new drug development, at the joint headquarters of Danaher China.

The two parties announced that they will launch full-chain in-depth cooperation in the cell and gene therapy (CGT) field to "Wielding the Blade of Precision, Upholding the Shield of Safety"As the core concept, jointly provide innovative pharmaceutical companies with an end-to-end (End-to-End) one-stop solution from底层编辑工具 to clinical translational safety evaluation, accelerating the next generation of innovative therapies across the IND/BLA submission thresholds."

Hu Xiangyu, President of China Region, Danaher Life Sciences Platform; Wei Chunyan, Vice President of Danaher External Affairs Department; Steven Henck, Global Chief Technology Officer of IDT; Wu Jianhua, General Manager of IDT China; Zhu Lin, Senior Director of Strategic Marketing, Danaher China Life Sciences Platform; Fu Yunbin, Director of Danaher External Affairs Department; Ji Xuwo, Founder and CEO of Precision Scientific; Zheng Xiaowan, Vice President; Li Zhe, Vice President, and other senior executives from both parties attended and witnessed this important moment.

In recent years, the CGT track has developed rapidly, but how to improve gene editing efficiency and strictly control off-target effects has always been a pain point困扰 pharmaceutical companies. At the signing ceremony,IDT General Manager for China, Jason WuShared the successful experience of IDT empowering the local innovation pipeline: "By introducing IDT's exclusively optimized CRISPR enzyme combined with high-purity gRNA, we have helped customers construct a technical pathway that balances high editing efficiency with low off-target effects. The high-fidelity and highly consistent underlying technology of IDT is precisely the 'precise blade' that assists pharmaceutical companies in breaking through at the forefront of R&D."

Precision Scientific Founder and CEO Ji Xuwo"In his speech, he stated: 'In the past few years, many promising CGT projects have been hindered by safety or efficacy issues. In the long cycle of drug development, we not only need a sharp "knife" but also an unbreakable "shield of safety." As a translational medicine platform with "multi-omics + AI" as its core technology, Precision Scientific has deep expertise in generative AI design, multi-omics analysis, efficacy evaluation, and safety assessment, providing comprehensive services for CGT from the preclinical stage (innovative target evaluation, vector optimization, sgRNA analysis, off-target effect assessment) to the clinical trial stage (clinical development strategy formulation, central laboratory testing). Through this strong collaboration with IDT, we will seamlessly integrate top-tier foundational tools into Precision Scientific's clinical translation system, converting data into actionable strategic insights to guide regulatory submissions. Together, we will provide customers with holistic solutions that meet the highest regulatory standards (FDA/CDE), enhancing the certainty of the submission pathway. The future is here; let us join hands to build a new CGT ecosystem.'"

In addition, Steven Henck, IDT's Global Chief Technology Officer, shared the latest evolutionary trends in gene editing technology from a global perspective and highly valued the cooperation between the two parties in the global CGT innovation chain.

This collaboration is not only a powerful alliance between two enterprises, but also an important milestone in the construction of Danaher's life science platform and its local innovation ecosystem in China.Xiangyu Hu, President of Danaher Life Sciences Platform in ChinaAs pointed out in the strategic outlook: "Facing the complex development of CGT drugs, we need to take one step further forward, shifting from 'providing top-tier tools' to 'delivering end-to-end solutions.' Today’s collaboration between IDT and Precision Scientific represents the deep integration of internal and external resources by the Danaher Life Sciences platform, acting as a 'connector' within the industry ecosystem. This is not only a new paradigm for implementing our 'Creating and Elevating China' strategy, but also a firm commitment to join hands with top local innovative forces to accelerate the market entry of next-generation innovative therapies, benefiting a wide range of patients."

After the signing ceremony, the attending guests jointly visited the Danaher Customer Experience Center, gaining further insights into the in-depth layout of Danaher's life science platform across the entire biopharmaceutical industry chain. In the future, IDT and Precision Scientific will continue to deepen their cooperation, jointly define new industry standards, and inject strong new momentum into China’s and even the global CGT industry.

Integrated DNA Technologies, Inc. (IDT) is an operating company under the life science platform of Danaher Corporation (NYSE: DHR). IDT develops, manufactures, and sells nucleic acid products for the life sciences community, supporting academic and commercial research, agriculture, medical diagnostics, and drug development. IDT has developed a number of patented technologies for genomic applications, including next-generation sequencing, CRISPR genome editing, synthetic biology, digital PCR, and RNA interference. Through its GMP services, IDT's products are used by scientists to study various forms of cancer as well as genetic and infectious diseases. As a leader in custom nucleic acid production, IDT serves more than 130,000 life science researchers.

IDT Edite was founded in 1987, with its production headquarters located in Coralville, Iowa, USA, and manufacturing facilities in San Diego, California, USA; Research Triangle Park, North Carolina, USA; Leuven, Belgium; and Singapore.

Precision Scientific is a platform company driven by "multi-omics + AI" to provide innovative pharmaceutical R&D services.

The company has built the advanced AIBERT platform, which provides pharmaceutical companies with globally leading services in innovative target evaluation and clinical development strategy formulation (indication selection, novel biomarker discovery, drug resistance mechanism research, and combination therapy exploration) by mining massive multi-omics data. It also extends its offerings to include central laboratory testing and companion diagnostic development. Meanwhile, the company’s generative AI algorithm, ProT-Diff, integrates biological large models with diffusion models to design functional molecular sequences, including protein/peptide design and modification. Currently, the company has formed deep collaborations with multiple leading domestic and international pharmaceutical and biotech companies, facilitating the research and approval of various new drugs.

The company also relies on the technical advantages of "multi-omics + AI" to find innovative disease biomarkers, develop first-in-China/first-in-world testing products for clinical use, and support the clinical practice of precision medicine.